RNN Key Stats
- REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Oct 16
- Rexahn Pharma (RNN) Enters $5.3M Registered Direct Offering Street Insider Oct 11
- Rexahn Announces $5.3 Million At Market Registered Direct Offering Business Wire Oct 11
- Rexahn signs exclusive license agreement for Lipid-Coated Albumin Nanoparticle Oct 10
- Rexahn Pharmaceuticals In-Licenses Novel Oligonucleotide Targeted Drug Delivery Platform from Ohio State University Business Wire Oct 10
- Rexahn's Recent Clinical Data Points To A New And Better Chemotherapy Pill Seeking Alpha Oct 6
- 5 Stocks Under $10 Set to Soar Oct 3
- Rexahn announces publication of RX-3117 preclinical data Sep 30
- Rexahn Pharma (RNN) Reports Pre-Clinical Data for RX-3117 Street Insider Sep 30
- Rexahn Pharmaceuticals Announces Publication of Preclinical Data for Novel Anti-Cancer Compound RX-3117 Business Wire Sep 30
RNN Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Rexahn Pharmaceuticals is up 25.36% over the last year vs S&P 500 Total Return up 30.90%, AEterna Zentaris down 49.31%, and Novo-Nordisk up 11.92%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for RNN
Pro Strategies Featuring RNN
Did Rexahn Pharmaceuticals make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
Rexahn Pharmaceuticals, Inc., is a development stage biopharmaceutical company engaged in the development of novel treatments for cancer to patients.